Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisEXEL -1.49%88 EBIT per Share is $3.67 as of Jun. 2026. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,170 Biotechnology companies, Exelixis ranks better than 94.53% on this metric.
Exelixis's EBIT per Share for the
three
months ended in Jun. 2026 was $0.96.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $3.67.
During the past 12 months, the average EBIT per Share Growth Rate of Exelixis was 41.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 72.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 48.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Exelixis's EBIT per Share or its related term are showing as below:
EXEL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.1 Med: 7.35 Max: 72.1
Current: 72.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Exelixis was 72.10% per year. The lowest was -26.10% per year. And the median was 7.35% per year.
EXEL's 3-Year EBIT Growth Rate is ranked better than 94.53% of 1170
companies
in the Biotechnology industry
Industry Median: 15.35
vs EXEL: 72.10
Exelixis's EBIT for the
three
months ended in Jun. 2026 was $248 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Exelixis EBIT per Share Related Terms
Exelixis EBIT per Share Historical Data
* Premium members only.
The historical data trend for Exelixis's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (EXEL) has a EBIT per Share of $3.67 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Exelixis and its competitors. According to the industry distribution chart, Exelixis ranks #64 out of 1170 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Exelixis' EBIT per Share too high?
Exelixis' current EBIT per Share is $3.67. The Biotechnology industry median EBIT per Share is 15.35. Exelixis' value of $3.67 is 76.1% below this industry median. Based on the distribution chart, Exelixis ranks #64 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' EBIT per Share compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #64 out of 1170 companies for EBIT per Share. This places Exelixis in the top 6% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.35. Exelixis' value of $3.67 is 76.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exelixis's current EBIT per Share of $3.67 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Exelixis and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exelixis's current EBIT per Share is $3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.59 — trading 17.2% above its estimated fair value. The current EBIT per Share is $3.67 and 76.1% below the Biotechnology industry median of 15.35. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Exelixis (EXEL), the current EBIT per Share is $3.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (EXEL) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of $53.59 is trading 17.2% above its estimated GF Value™ of $45.73.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for EXEL:
EBIT per Share: $3.67
GF Value™: $45.73 vs. price of $53.59 (17.2% above fair value)
Industry Position: 76.1% below the Biotechnology median (#64 of 1170)
No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score
Get the complete analysis for EXEL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXEL has been successfully added to your 
